Neurology 2017-07-14T21:06:02+00:00

Neurology

Specialized patient populations that require unique or complex therapies will continue to make neurology the target for dynamic research and commercial markets. With a specific focus on the Multiple Sclerosis (MS) market in the US and the EU, Spherix is shedding light on the key dynamic issues in this fast moving category. The increased risk tolerance and the expanding number of therapies in multiple sclerosis is evolving the treatment strategies for all forms of MS.

Reports

Click the links below to download report overviews

Reports new KS-01

Survey of high dynamic markets, tracking brand usage, awareness, industry contacts and evolving perceptions.

RealTime Dynamix: Multiple Sclerosis US 2017 (quarterly)
RealTime Dynamix: Multiple Sclerosis EU 2017 (bi-annual)
RealTime Dynamix: Multiple Sclerosis Nurses US 2017 (annual)

 

Reports new KS-02

In-depth analysis of a robust sample of patient journeys detailing the realities of current practice.

RealWorld Dynamix: DMT New Starts in Multiple Sclerosis US 2017
RealWorld Dynamix: DMT Switching in Multiple Sclerosis US 2017
RealWorld Dynamix: Monoclonal Antibodies in MS US 2017
RealWorld Dynamix: mAb DMTs in MS US 2017